Swiss pharma giant Roche has released results from a pivotal trial comparing Alecensa with the standard of care in lung cancer, which show a marked improval in 6 June 2017
Tagrisso (osimertinib).the potential new standard-of-care for locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non 6 June 2017
As the annual meeting of the American Society of Clinical Oncology enters its final day, US biotech major Celgene has released data on two of its co-development 6 June 2017
Hutchison China MediTech has announced results from its pivotal Phase III trial of fruquintinib, its novel vascular endothelial growth factor receptor (VEGFR) k 6 June 2017
Taking three-month breaks during long-term treatment with letrozole did not reduce the risk of recurrence of breast cancer compared with taking the aromatase in 5 June 2017
Swiss pharma giant Roche presented data showing that fewer patients with HER2-positive breast cancer see their disease return after adding Perjeta (pertuzumab) 5 June 2017
America’s Merck & Co will today present an additional five months of follow-up data on Keytruda in combination with pemetrexed and carboplatin (pem/carbo), in t 5 June 2017
Privately-held German pharma Boehringer Ingelheim has presented encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma (MPM) at ASC 5 June 2017
At the annual meeting of the American Society of Clinical Oncology, Japanese pharma major Eisai has released data from a Phase III study into Lenvima as a first 5 June 2017
US biotech Amgen on Sunday announced new data from the Xgeva (denosumab) Phase III ‘482 study, the largest international multiple myeloma trial ever conducted. 4 June 2017
In what could be one of the most significant advances announced at the 2017 ASCO Annual Meeting, AstraZeneca has presented the first positive Phase III data on 4 June 2017
US pharma major Eli Lilly has added to its body of data on abemaciclib in breast cancer as it seeks to gain ground on rivals in the cyclin-dependent kinase (CDK 4 June 2017
Eagerly-anticipated data from an ongoing Phase I/II trial into epacadostat in combination with Keytruda have been released, as the annual meeting of the America 4 June 2017
Bristol-Myers Squibb has announced data from a Phase II trial evaluating Opdivo as a monotherapy and in combination with Yervoy, in colorectal cancer (CRC). 4 June 2017
Top-line data from Janssen’s eagerly-awaited clinical trial into Zytiga in combination with the standard of care for advanced prostate cancer have been released 4 June 2017
Phase III data on Anglo-Swedish pharma major AstraZeneca’s (LSE.AZN) of Lynparza (olaparib) 300mg twice-daily tablet maintenance treatment shows that quality of 2 June 2017
With data so many innovative but expensive new oncology treatments being presented at ASCO 2017.it is a crucial period for biosimilars of three of the world's b 1 June 2017
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.